NCT07941622
Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Timeframe: Day181
Secondary (11)
Baseline, pre-vaccination sample
1 month after the last dose of primary series:
Before the booster dose:
1 month after the booster dose:
Presence of immediate unsolicited adverse events (AEs)
Show 6 moreShow less
Presence of solicited injection site reactions
Presence of solicited systemic reactions
Presence of unsolicited AEs
Presence of serious adverse events (SAEs)
Presence of related SAEs and fatal case regardless of causality
Presence of AEs leading to study discontinuation
Arms and interventions
Group 1 (the investigational group)Experimental
Hexaxim at 2, 4 and 6 MoA
Group 2 (the comparator group)Active comparator
Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA
Biologicals: DTaP-IPV-HB-PRP~T combined vaccine, DTaP-IPV//PRP~T combined vaccine, monovalent Hep B vaccine